Core Insights - The report emphasizes the importance of discovering investment opportunities with a proactive attitude rather than merely relaying information [1] Macro News Summary - The State Council has issued implementation opinions to improve the national unified electricity market system, encouraging more private enterprises to participate in the electricity market [4] - The Ministry of Commerce stated that China and the U.S. maintain close communication at all levels through the economic and trade consultation mechanism [4] - The National Energy Administration highlighted that major global economies are actively laying out hydrogen energy and nuclear fusion, necessitating greater efforts to enhance original disruptive innovation [4] Industry Latest Developments - Ant Group's Alipay has launched a Spring Festival red envelope activity, with the AI healthcare sector expected to gain momentum, related stocks include Sanor Bio (300298) and Huaren Health (301408) [5] - Strong demand for memory is expected to continue until 2027, with opportunities for domestic storage development emerging, related stocks include Lanke Technology (688008) and Aisen Co. (688720) [5] - Domestic large models are being launched intensively, with the AI computing power sector showing promising growth and certainty, related stocks include UCloud (688158) and Shenxinfu (300454) [5] Company Focus - Wanrun Co. (002643) has commenced trial production of a PEI product production line with an annual capacity of 1,500 tons [6] - Zhiguang Electric (002169) expects its independent energy storage power station (Phase I) to commence commercial operation within the first quarter [6] - Deshi Co. (301158) has seen its ultra-wear-resistant high-pressure acidification fracturing hose widely applied in North America, while domestic usage is still in small-scale trials [6] - Jiawei New Energy (300317) successfully connected a 3.73MW distributed photovoltaic project in Guangxi Wuzhou to the grid [6] Market Review and Outlook - On February 12, major indices collectively rose, with the ChiNext Index and the Sci-Tech Innovation 50 Index both increasing by over 1%. The total trading volume in the Shanghai and Shenzhen markets reached 2.14 trillion, an increase of 157.5 billion from the previous trading day [7] - The computing power industry chain experienced a collective surge, with concepts related to computing power leasing gaining strength. Stocks like Dawi Technology saw a four-day consecutive rise, while UCloud hit a 20% limit up [7] - The consumer sector faced declines, particularly in film and television, tourism, retail, and food and beverage, with stocks like Hengdian Film and Haixin Food hitting the limit down [7] - The current spring market remains promising, with potential favorable news expected in the coming months, although a brief period of market correction may occur before the Spring Festival due to tightening liquidity and reduced trading enthusiasm [7]

Group 1 - The AI medical sector increased by 0.24% compared to the previous trading day, with Youke De leading the gains [1] - The Shanghai Composite Index closed at 4134.02, up 0.05%, while the Shenzhen Component Index closed at 14283.0, up 0.86% [1] - The net inflow of main funds in the AI medical sector was 863 million yuan, while retail funds experienced a net outflow of 47.14 million yuan [1] Group 2 - The table detailing the individual stock performance within the AI medical sector was referenced but not included in the summary [1] - The data was compiled by Securities Star using public information and generated by AI algorithms [1]

Core Viewpoint - 九州通's subsidiary received approval for the listing application of Betahistine Dihydrochloride Tablets, which are used for Meniere's disease and cerebral vascular diseases, indicating potential growth in product offerings to meet aging population needs [1] Recent Events - 九州通 announced that its controlling shareholder, Chuchang Investment, has prematurely released the pledge of 11.3 million shares (2.46% of its holdings), while a related party, Shanghai Hongkang, pledged 11.7 million shares (1.08% of its holdings). As of the announcement date, the total pledged shares by Chuchang Investment accounted for 57.29% of its holdings and 26.03% of the company's total share capital [2] - The company is positioned as a digital service provider in the AI medical ecosystem, supporting the Ant Group's supply chain, with over 50 million orders in 2025, reflecting a 180% year-on-year increase [2] Stock Performance - As of February 12, 2026, 九州通's stock price was 5.21 yuan, with a cumulative decline of 1.14% over the past five days and a price fluctuation of 2.66%. The net outflow of main funds was 11.51 million yuan, with a turnover rate of 0.23%. The technical analysis indicates the stock is in a consolidation phase, with a 20-day moving average of 5.31 yuan, a Bollinger Band resistance level of 5.56 yuan, and a support level of 5.08 yuan [3] Institutional Viewpoints - The market is focusing on the integration of AI medical technology and pharmaceutical distribution digitalization. 九州通 is enhancing supply chain efficiency through smart warehousing and blockchain technology, with its pharmaceutical industrial business generating 2.3 billion yuan in revenue in the first three quarters of 2025, a year-on-year increase of 9.93%. However, there is uncertainty regarding the approval results for the newly accepted drugs [4]

Group 1 - The Hong Kong stock market for innovative drugs experienced a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping by 2%, and major stocks like CSPC Pharmaceutical, China Biologic Products, and Hansoh Pharmaceutical falling over 2% [1] - The market is expected to see a traditional surge during the Chinese New Year holiday, with an average increase of 2% since 2021 [1] - CICC highlights four key sectors in the A-share market: dividends, internet, innovative drugs, and new consumption, which are considered to have long-term investment value [1] Group 2 - Chinese innovative drugs continue to gain traction internationally, with significant business development (BD) deals, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [2] - In January, CSPC Pharmaceutical announced a partnership with AstraZeneca valued at up to $18.5 billion, showcasing the global competitiveness of Chinese innovative drugs [2] Group 3 - The Chinese innovative drug sector is entering a commercialization phase, with over 70% of innovative drug companies reporting revenue growth, and companies like BeiGene achieving revenues exceeding 36 billion yuan [3] - Leading companies are starting to achieve profitability, with firms like Innovent Biologics and Rongchang Biologics reaching annual breakeven, and Elysium achieving over 2 billion yuan in net profit [3] - Open Source Securities expresses optimism about the innovative drug sector and its supply chain, as well as emerging industries like AI and biomanufacturing [3] Group 4 - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity, particularly through ETFs for efficient capital allocation [3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) focuses on innovative drug R&D companies, with the top ten holdings accounting for over 73% of the portfolio [3]

行业政策现状 据市场分析，2026年下半年医疗保健行业政策将密集落地，包括医保支付扩容、癌症早筛推广和AI医 疗规模化支持，这些可能为美年健康带来客户增量及营收增长机会。 股票近期走势 经济观察网美年健康（002044）近期拟参与棒杰股份（002634）预重整以整合产业链，同时其AI医疗 业务收入增长迅速，并受益于行业政策预期。近期股价表现活跃，资金关注度较高。 2026年2月10日，美年健康股价上涨2.41%，主力资金净流入2091.40万元，成交额7.84亿元。今年以来 股价累计上涨36.74%，显示资金关注度较高。 以上内容基于公开资料整理，不构成投资建议。 近期事件 2026年1月29日，美年健康公告拟报名参与棒杰股份的预重整，并指定全资子公司美年大健康作为重整 受让主体，目标取得棒杰股份的控制权。此举旨在整合产业链资源，构建"服务—硬件—数据"三位一体 模式，拓展健康管理新业态。但公司提示，是否具备参与资格及最终成为重整投资人存在不确定性。 业务进展情况 2026年1月9日，受OpenAI推出"ChatGPTHealth"等功能催化，AI医疗主题投资热情升温。美年健康的AI 产品和"健康小美"系统已 ...

Industry News - DeepSeek has updated its web and app versions to support a maximum context length of 1 million tokens, an increase from the previous 128K tokens in version 3.1 released last August [3] - The chief scientist of the China Automotive Technology and Research Center announced that the draft for GB/T "Solid-State Batteries for Electric Vehicles Part 1: Terminology and Classification" will be completed by December 2025, with a public consultation period ending on February 28, 2026 [3] - According to central bank data, by the end of 2025, the Shanghai Composite Index is expected to close at 3968.8 points, an increase of 18.4% from the end of 2024, while the Shenzhen Component Index is projected to reach 13525.0 points, up 29.9% [3] - The international oil prices have recently shown an upward trend, with significant premiums observed in oil funds. South Fund has adjusted the purchase limit for its oil fund to 1 yuan [3] - In January 2026, China's automotive industry maintained stable operations, with production and sales reaching 2.45 million and 2.346 million units respectively, with production increasing by 0.01% year-on-year and sales decreasing by 3.2% [4] Company News - Zhongji Xuchuang stated on its interactive platform that CSP customers place orders directly with the company, with no middlemen involved [5] - Giant Lifting announced that it has not signed a 4.58 billion project in Hainan, and its total orders in the commercial aerospace sector for 2025 amount to 9.9651 million yuan [6] - NetEase reported an operating profit of 35.8 billion yuan for 2025, representing a year-on-year increase of 21% [6] - Tianqi Mould announced plans to acquire 60% of Dongshi shares, and its stock has resumed trading [6] - The company Kaiying Network signed a settlement agreement with the legendary IP, which is expected to have a positive impact of approximately 200 million yuan on its current profits [12] - Newray announced plans to acquire 70% of PCB tool company Hui Lian Electronics for no more than 700 million yuan [12] - Longbai Group plans to acquire 5.46% of Yunnan Guotai's shares for 234 million yuan [12] - Dazhi Technology announced that its Zhangbei data center project will not involve computing power leasing business [12]

早 报 精 选 1、李强：全面推进人工智能科技创新、产业发展和赋能应用，培育壮大新质生产力。 2、国务院：到2035年全面建成全国统一电力市场体系。 3、国务院国资委：央企要积极扩大算力有效投资。 4、DeepSeek更新，上下文达百万级token。 5、巨力索具公告，未签署过4.58亿的海南项目。 宏 观 新 闻 1、2月11日，国务院以深化拓展"人工智能+"、全方位赋能千行百业为主题，进行第十八次专题学习。国务院总理李强在主持学习时 强调，要深入学习贯彻习近平总书记关于人工智能发展的重要指示精神和党中央有关决策部署，全面推进人工智能科技创新、产业发 展和赋能应用，培育壮大新质生产力，推动高质量发展。 2、国务院办公厅日前印发《关于完善全国统一电力市场体系的实施意见》。《意见》指出，推动电力资源在全国范围内优化配置， 优化全国统一电力市场体系实现路径，完善跨省跨区电力交易制度。《意见》还提出，到2035年，全面建成全国统一电力市场体 系，市场功能进一步成熟完善，市场化交易电量占比稳中有升。 3、国务院国资委日前提出，中央企业要强化投资牵引，积极扩大算力有效投资，推进"算力+电力"协同发展，提升全链条数据治理 ...

Core Insights - The report emphasizes the focus on undervalued and performance-recovering sectors within the medical services and consumer segments, predicting a fundamental improvement in 2026 [4]. Group 1: Investment Strategy - The report maintains an "outperform" rating for the sector, indicating a positive outlook for the medical and consumer-related segments [2]. - Key areas of focus include medical services, pharmacies, and home medical devices, which are expected to see performance recovery and valuation improvements in 2026 [4]. Group 2: Sector Analysis - Medical services are anticipated to recover due to improved supply structure and consumer environment, with leading companies expected to show positive earnings guidance for 2026 [4]. - The pharmacy sector has shown significant marginal improvement since Q3 2025, with leading companies experiencing quarterly performance enhancements [4]. - Home medical devices are expected to benefit from increased product penetration and domestic production rates, contributing to sustained performance growth [4]. Group 3: Notable Companies - The report highlights specific companies to watch, including Aier Eye Hospital, Yuyue Medical, and Yifeng Pharmacy, which are positioned for growth in their respective segments [4]. - The investment portfolio for February 2026 includes a mix of A-share and H-share companies, such as Mindray Medical, WuXi AppTec, and Kangfang Biotech, indicating a diversified approach to investment [4]. Group 4: Market Performance - The medical sector outperformed the broader market in January 2026, with a 3.14% increase compared to the 1.49% rise of the CSI 300 index [10]. - Sub-sectors such as medical services and medical devices showed significant gains, with respective increases of 8.82% and 5.28% [17]. Group 5: Macro Data - In 2025, the pharmaceutical manufacturing industry reported a total revenue of 24,870 billion yuan, reflecting a slight decline of 1.2% year-on-year, while total profits increased by 2.7% [9]. - The retail sales of pharmaceuticals reached 7,294 billion yuan, with a year-on-year growth of 1.8%, indicating a stable demand in the market [9].

Company Summary - Yidu Tech (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Yidu Tech achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's "2025 Artificial Intelligence Medical Device Innovation Task" list with a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting that 2026 will likely see greater certainty in AI medical commercialization and open up new commercial opportunities [1][1][1] - Key areas to focus on include AI pharmaceuticals, grassroots AI medical applications, medical data circulation and trading, AI pathological diagnosis, AI medical models, and C-end expansion channels, along with related targets [1][1][1]

Company Summary - Medicure Technology (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Medicure Technology achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's 2025 AI medical device innovation project list with a multimodal AI database project for gastrointestinal tumor diagnosis and treatment in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting a stronger certainty for AI medical commercialization in 2026 [1][1][1] - Key areas for investment focus include AI drug development, grassroots AI medical applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1][1][1]